Revenue (Tables)

9 Months Ended

Mar. 31, 2020

Revenue From Contract With Customer [Abstract]

Composition of Total Revenue by Product and by U.S versus Rest of World

The following table presents detail regarding the composition of our total revenue by product and by U.S versus rest of world, “RoW”:

	Three months ended March 31,
	2020						2019
(In millions)	U.S.		RoW		Total		U.S.		RoW		Total
Molecular diagnostic revenues:
Hereditary Cancer Testing	$	81.3	$	3.9	$	85.2	$	114.3	$	3.3	$	117.6
GeneSight		20.4		—		20.4		29.6		—		29.6
Prenatal		20.2		0.1		20.3		30.6		—		30.6
Vectra		10.5		—		10.5		11.3		—		11.3
Prolaris		6.8		—		6.8		6.9		—		6.9
EndoPredict		0.6		2.9		3.5		0.5		2.3		2.8
Other		3.6		0.2		3.8		1.5		0.2		1.7
Total molecular diagnostic revenue		143.4		7.1		150.5		194.7		5.8		200.5
Pharmaceutical and clinical service revenue		9.6		3.9		13.5		9.7		6.4		16.1
Total revenue	$	153.0	$	11.0	$	164.0	$	204.4	$	12.2	$	216.6

	Nine months ended March 31,
	2020						2019
(In millions)	U.S.		RoW		Total		U.S.		RoW		Total
Molecular diagnostic revenues:
Hereditary Cancer Testing	$	295.0	$	12.6	$	307.6	$	351.4	$	9.3	$	360.7
GeneSight		65.6		—		65.6		82.8		—		82.8
Prenatal		59.9		0.2		60.1		80.0		—		80.0
Vectra		31.8		—		31.8		36.1		—		36.1
Prolaris		20.0		0.1		20.1		19.1		0.1		19.2
EndoPredict		1.5		6.8		8.3		1.2		6.2		7.4
Other		9.9		0.2		10.1		5.8		0.5		6.3
Total molecular diagnostic revenue		483.7		19.9		503.6		576.4		16.1		592.5
Pharmaceutical and clinical service revenue		26.3		15.5		41.8		25.5		17.7		43.2
Total revenue	$	510.0	$	35.4	$	545.4	$	601.9	$	33.8	$	635.7

Reconciliation of Deferred Revenue Balances

A reconciliation of the beginning and ending balances of deferred revenue is shown in the table below:

	Nine months ended
	March 31,
	2020			2019
Deferred revenue - beginning balance	$	2.2		$	2.6
Revenue recognized		(2.4	)		(5.9	)
Prepayments		4.0			5.6
Deferred revenue - Ending Balance	$	3.8		$	2.3